PCYT2 and metabolic dysfunction-associated steatohepatitis: We have previously shown that an 8-week treatment with the artificial Pcyt2 substrate PEA prevents and/or reverses multiple aspects of the Pcyt2 + /- NASH phenotype including liver steatosis, inflammation, and the protein levels of several glucose and fatty acids metabolic regulators [16].